Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Form 8.5 (EPT/RI) - PPHE Hotel Group Limited
-
Fischer Sciences Launches Code of Culture Probiotics Across U.S. & Canada Amid Rising Consumer Demand for whole food probiotics
-
Digital Empowerment for Traditional TCM – Laozhongyi and CUBE Platform Forge Strategic Partnership to Expand into Southeast Asia and the Middle East
-
Neinor Homes announces an orderly leadership transition with the appointment of Jordi Argemí as CEO from 2027
-
RAMSAY SANTE : Half-year Financial Report as at end of December 2025 disposal
-
AKVA group ASA: New land based contract signed with Laxey
-
Go Rentals Named Official Luxury Car Provider for 2026 HITS Equestrian Show Series
-
Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ADCs at AACR 2026
-
ESET Research: New NGate hides in NFC payment app, possibly built with AI
-
Homary Presents “Your Life: Beautifully Practical” at Grand Designs Live London 2026
-
Q1 2026 trading statement
-
Prosafe SE: Operational update – March 2026
-
Form 8.3 - [ADVANCED MEDICAL SOLUTIONS PLC - 20 04 2026] - (CGWL)
-
RESULT OF RIKSBANK CERTIFICATE SALE
-
Form 8.3 - [IDOX PLC - 20 04 2026] - (CGWL)
-
ISN® Celebrates 15 Years of Supporting Hiring Organisations and Contractors Across Europe
-
Form 8.3 - [ANIMALCARE GROUP PLC - 20 04 2026] - (CGWL)
-
Form 8.3 - [ADVANCED MEDICAL SOLUTIONS PLC - Opening Disclosure - 20 04 2026] - (CGAML)
-
Successful wind repowering in Spain achieves 98 percent waste recovery
-
Net Asset Value
-
Transactions in connection with share buy-back program
-
Introducing Osirus AI, the Unified Platform for Building, Deploying, and Managing Enterprise AI Agents
-
Dimensional Fund Advisors Ltd. : Form 8.3 - ADVANCED MEDICAL SOLUTIONS - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - CAPRICORN ENERGY PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - SPIRE HEALTHCARE GROUP PLC - Ordinary Shares
-
Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit™, as it moves to commercialization
-
Advantest Announces Strategic Partnership with Applied Materials and Joins EPIC Platform
-
Publication of eQ Plc’s Q1 2026 interim report and invitation to result presentation
-
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
-
Applied Materials Announces Advantest as Innovation Partner for EPIC Platform in Silicon Valley
-
creditpath.io Expands Advisor First Credit Platform with New Lending Solutions and Capital Access
-
Watershed Launches New AI Agents and Sustainability AI Fellowship
-
Payment Failures Put £1.7 Billion in UK Retail & Hospitality Sales at Risk Each Year
-
Eclipse Foundation Launches Open VSX Managed Registry
-
Teledyne e2v introduces the Caiman module: a compact imaging solution for low light imaging
-
New final terms for Euro Medium Term Note - Nykredit Realkredit A/S
-
Hamilton Global Opportunities plc (ALHGO.PA) published its 2025 full-year financial results and activity report
-
Royal Unibrew and PepsiCo to end the partnership in Northern Europe upon expiry of current license agreements
-
Grady Manual Therapy Ltd Champions "Exercise is Medicine" to Deliver Professional Sports Health Care to Everyday Athletes in Hong Kong
-
Groundbreaking approaches such as cell therapies on the horizon for transformation of neural hearing loss, Rinri Therapeutics’ review1 shows
-
98% of Enterprises Prioritize Digital Sovereignty, with More Than Half Taking Action
-
VAALCO Energy, Inc. Announces Positive Operational Update
-
SUSE Launches SUSE AI Factory with NVIDIA
-
Pulsar Helium Announces the Appointment of DGWA as European Financial Markets and Corporate Advisor
-
Cabka Reports Solid Start to 2026 With Improved Profitability in Q1
-
Aspocomp will publish its Interim Report for January–March 2026 on Wednesday April 29, 202
-
NBPE Announces Transaction in Own Shares
-
Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
-
Total Voting Rights and Transaction in Own Shares
-
Progress on share buyback programme

